Evommune (EVMN) Cash from Financing Activities (2024 - 2026)

Evommune (EVMN) has 3 years of Cash from Financing Activities data on file, last reported at $117.1 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $117.1 million, up 77146.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $323.5 million (changed N/A YoY), and the FY2025 annual result was $220.8 million, up 346.72% from the prior year.
• Cash from Financing Activities eased to $117.1 million in Q1 2026 per EVMN's latest filing, from $156.8 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $156.8 million in Q4 2025 and troughed at -$152000.0 in Q1 2025.
• A 3-year average of $80.9 million and a median of $83.4 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities surged 215.58% in 2025, then jumped 77146.71% in 2026.
• A 3-year view of Cash from Financing Activities shows it stood at $49.7 million in 2024, then surged by 215.58% to $156.8 million in 2025, then decreased by 25.33% to $117.1 million in 2026.
• Business Quant data shows EVMN's Cash from Financing Activities at $117.1 million in Q1 2026, $156.8 million in Q4 2025, and -$152000.0 in Q1 2025.